Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameKintor Pharma-B
Stock Code09939
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是中國一家臨床階段新藥開發商,專注於自主研發潛在同類首創及同類最佳癌症藥物及其他雄激素受體相關(或AR相關)疾病藥物。
Listing Date2020-05-22
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國江蘇省蘇州市蘇州工業園區星湖街218號生物納米園C4幢401室
Business Address (Hong Kong)香港九龍海港城港威大廈第二座20樓2007室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.kintor.com.cn
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 20.15 / shares
Offer Price RangeFinal offer price only, no range
Lot Size500 shares
Entry ThresholdHK$ 10,075
Par ValueTo be extracted
Offer Period2020-05-12 to 2020-05-15
Global Offering Shares92,347,500 shares
HK Public Offer Shares (Initial)9,235,000 shares (10.0%)
Public Offer Lots (Initial)18,470lots (Pool A9,235lots,Pool B9,235lots)
International Placing Shares (Initial)83,112,500 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO369,389,600 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share47.9%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 1,860,802,125

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 500 HK$ 10,075
2 lots 1,000 HK$ 20,150
3 lots 1,500 HK$ 30,225
4 lots 2,000 HK$ 40,300
5 lots 2,500 HK$ 50,375
6 lots 3,000 HK$ 60,450
7 lots 3,500 HK$ 70,525
8 lots 4,000 HK$ 80,600
9 lots 4,500 HK$ 90,675
10 lots 5,000 HK$ 100,750
12 lots 6,000 HK$ 120,900
14 lots 7,000 HK$ 141,050
16 lots 8,000 HK$ 161,200
18 lots 9,000 HK$ 181,350
20 lots 10,000 HK$ 201,500
30 lots 15,000 HK$ 302,250
40 lots 20,000 HK$ 403,000
50 lots 25,000 HK$ 503,750
60 lots 30,000 HK$ 604,500
70 lots 35,000 HK$ 705,250
80 lots 40,000 HK$ 806,000
90 lots 45,000 HK$ 906,750
100 lots 50,000 HK$ 1,007,500
110 lots 55,000 HK$ 1,108,250
120 lots 60,000 HK$ 1,209,000
130 lots 65,000 HK$ 1,309,750
140 lots 70,000 HK$ 1,410,500
150 lots 75,000 HK$ 1,511,250
160 lots 80,000 HK$ 1,612,000
170 lots 85,000 HK$ 1,712,750
180 lots 90,000 HK$ 1,813,500
190 lots 95,000 HK$ 1,914,250
200 lots 100,000 HK$ 2,015,000
400 lots 200,000 HK$ 4,030,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
600 lots 300,000 HK$ 6,045,000
800 lots 400,000 HK$ 8,060,000
1,000 lots 500,000 HK$ 10,075,000
1,200 lots 600,000 HK$ 12,090,000
1,400 lots 700,000 HK$ 14,105,000
1,600 lots 800,000 HK$ 16,120,000
1,800 lots 900,000 HK$ 18,135,000
2,000 lots 1,000,000 HK$ 20,150,000
4,000 lots 2,000,000 HK$ 40,300,000
6,000 lots 3,000,000 HK$ 60,450,000
8,000 lots 4,000,000 HK$ 80,600,000
9,235 lots 4,617,500 HK$ 93,042,625

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 1.07B
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +811%

Valuation & Financials

Market Cap (at Offer Price)HK$ 7,443,200,439
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status虧損人民幣232.6百萬元
Period-End Cash Balance人民幣195.5百萬元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 20182019
Revenue 6980
Cost of sales -6890
Gross profit 90
Other income and gains, net 12,29819,018
Selling and distribution expenses 0-336
Administrative expenses -24,104-32,763
Operating profit -104,477-228,687
Net finance costs -4,007-3,890
Profit before tax -108,484-232,577
Income tax expense 00
Profit for the year -108,484-232,577
Profit attributable to owners -108,484-232,577
Balance Sheet
Item 20182019
Cash and cash equivalents 137,513195,532
Total current assets 218,343220,613
Total assets 423,597553,376
Total current liabilities 108,385142,583
Total liabilities 171,920183,712
Total equity 251,677369,664
Equity attributable to owners 251,677369,664
Interest-bearing borrowings 65,00058,700
Cash Flow Statement
Item 20182019
Net cash from operating activities -114,868-228,042
Net cash from investing activities -64,748-7,013
Net cash from financing activities 303,936295,852
Net increase in cash 124,32060,797
Purchase of PP&E -5,249-67,241
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 21.5
First Day OpenHK$ 20.15
First Day Change6.70%
First Day Volume68937600.0
First Day Turnover1484110000.0
Use of Proceeds
1、約42%所得款項凈額(約734.0百萬港元)分配至我們的其中一種核心產品普克魯胺的開發及商業化; 2、約28%所得款項凈額(約489.3百萬港元)分配至我們的其中一種核心產品福瑞他恩的開發及商業化; 3、約4%所得款項凈額(約69.9百萬港元)分配至開發我們的臨床階段在研藥物ALK-1; 4、約4%所得款項凈額(約69.9百萬港元)分配至開發我們的臨床階段在研藥物迪拓賽替; 5、約4%所得款項凈額(約69.9百萬港元)分配至開發我們的臨床階段在研藥物GT1708F(Hedgehog/SMO抑制劑); 6、約2%所得款項凈額(約35.0百萬港元)分配至其他臨床研究項目; 7、約6%所得款項凈額(約104.8百萬港元)分配至我們臨床前階段在研藥物的研發; 8、約10%所得款項凈額(約174.7百萬港元)分配至我們的營運資金及一般企業用途。

Underwriting Syndicate

Sole Sponsor (1)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
Overall Coordinators (3)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 UBS Securities Hong Kong Limited CE BIN466 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Joint Bookrunners (8)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 UBS Securities Hong Kong Limited CE BIN466 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 招银国际融资有限公司 CE AVM940 China Renaissance Securities (Hong Kong) Limited CE AZX839 海通国际证券有限公司 CE AAF806 建银国际金融有限公司 CE AJO225 CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536
Joint Lead Managers (11)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 UBS Securities Hong Kong Limited CE BIN466 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 招银国际融资有限公司 CE AVM940 China Renaissance Securities (Hong Kong) Limited CE AZX839 海通国际证券有限公司 CE AAF806 建银国际金融有限公司 CE AJO225 CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536 SPDB International Capital Limited CE BFZ375 富途证券国际(香港)有限公司 CE AZT137 FTFT International Securities and Futures Limited CE ATR516

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Cherry Cheeks HK Limited 54,253,875 HKD — 2.92% — 6 months 2020-11-22
2 Foresight Orient Global Superior Choice SPC 38,748,450 HKD — 2.08% — 6 months 2020-11-22
3 Highlight Medical Limited 38,748,450 HKD — 2.08% — 6 months 2020-11-22
4 珠海格力金融投资管理有限公司 759,584,475 HKD — 40.82% — 6 months 2020-11-22

Directors & Management

PositionChinese nameEnglish Name
Chairman童友之—
Company Secretary陳潔、楊靜文—
No director data available.

Major Shareholders

Major Shareholders & Holdings童友之及郭創新為一致行動人士,通過各自全資公司KT International及KG Development分別持有緊隨全球發售完成後約27.64%及27.64%股份(假設超額配股權未獲行使)。
About this page

This page shows Kintor Pharma-B (09939) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect